Currently, GFRα4-CAR-T cells are being evaluated in a Phase I clinical trial (NCT04877613) for adults with recurrent/metastatic MTC who received ≥ 1 prior tyrosine kinase inhibitor regimen or declined such therapy. Here, GFRA4 is linked to medullary thyroid gland carcinoma.